Records containing: Neuroblastoma

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

All FDA submission records EMA medicine records ClinicalTrials.gov record updates ClinicalTrials.gov records with results posted

CLINICAL_TRIALS study record update · 2025-12-04
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study
CLINICAL_TRIALS study record update · 2025-12-03
Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment After Autologous Hematopoietic Stem Cell Transplantation in Children With Neuroblastoma
CLINICAL_TRIALS study record update · 2025-12-03
NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma
CLINICAL_TRIALS study record update · 2025-12-03
18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
CLINICAL_TRIALS study record update · 2025-11-24
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
Organize your saved records without ads with Plus.
CLINICAL_TRIALS study record update · 2025-11-24
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
CLINICAL_TRIALS study record update · 2025-11-20
Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
CLINICAL_TRIALS study record update · 2025-11-20
Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
CLINICAL_TRIALS study record update · 2025-11-18
A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.
CLINICAL_TRIALS study record update · 2025-11-04
Genomic Structural Variation in Cancer Susceptibility
CLINICAL_TRIALS study record update · 2025-11-03
Fecal Microbiota Transplant for Neuroblastoma in a Single Patient
CLINICAL_TRIALS study record update · 2025-10-22
A Phase I Study of 131-1 mIBG Followed by Nivolumab and Dinutuximab Beta in Children With Relapsed/Refractory Neuroblastoma
CLINICAL_TRIALS study record update · 2025-10-21
Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
CLINICAL_TRIALS study record update · 2025-10-16
TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors
CLINICAL_TRIALS study record update · 2025-10-15
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
CLINICAL_TRIALS study record update · 2025-10-10
Phase I/II Multicenter Study to Assess Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
CLINICAL_TRIALS study record update · 2025-10-07
Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin for Consolidation of First Remission of Patients With High-Risk Neuroblastoma: A Phase II Study
CLINICAL_TRIALS study record update · 2025-09-29
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
CLINICAL_TRIALS study record update · 2025-09-26
the Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for the Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
CLINICAL_TRIALS study record update · 2025-09-23
Pilot Pharmacokinetic Study of VAL-413 (Orotecan®) in Patients With Recurrent Pediatric Solid Tumors
CLINICAL_TRIALS study record update · 2025-09-19
GD2 Specific Chimeric Antigen Receptor (CAR) and Interleukin-15 Expressing Autologous Natural Killer T-cells to Treat Children With Neuroblastoma
CLINICAL_TRIALS study record update · 2025-09-16
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial
CLINICAL_TRIALS study record update · 2025-09-15
Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients With ALK-Driven Relapsed or Refractory Neuroblastoma
CLINICAL_TRIALS study record update · 2025-09-12
Interest of Preoperative Arteriography to Identify the Adamkiewicz Artery Before Surgery for Basi-thoracic Neuroblastic Tumors
CLINICAL_TRIALS study record update · 2025-09-03
Fertility Preservation in Children With Neuroblastoma or Ewing's Sarcoma: Detection of Residual Disease by a Sensitive Method